Kopran Ltd Q3 FY26 – ₹194 Cr Revenue, ₹9.34 Cr PAT, EV/EBITDA 15.7×: Carbapenem-Fuelled Growth Meets Diagnostic Drama

1. At a Glance

If pharma companies were Bollywood characters, Kopran would be that serious-looking supporting actor who occasionally steals the scene—but also disappears for a few reels. Market cap sits around ₹658 crore, current price near ₹136, and the stock has punished impatient holders with a one-year return of roughly –32%. Yet Q3 FY26 delivered ₹194.28 crore revenue (YoY +16.9%) and ₹9.34 crore PAT, while margins stayed stubbornly single-digit. ROCE hovers near 9.75%, ROE at 7.64%, and debt-to-equity a manageable 0.31. Dividend yield? A respectable ~2.2%, because Kopran believes in paying rent even when profits sulk.

The headline act this quarter is Carbapenems (43.5% of Q1 FY26 segment revenue)—high-value APIs doing the heavy lifting—while formulations remain export-heavy. Add a merger with Kopran Laboratories (diagnostics angle), steady capex of ₹7–8 crore annually, and a recent SGST search (probe ongoing, no violations disclosed). Curious yet? You should be.

2. Introduction

Kopran has been around long enough to remember floppy disks—and it behaves like it. No flashy Gen-Z growth claims, just APIs, formulations, and a balance sheet that prefers chai over Red Bull. The company manufactures APIs and formulations and sells across 50+ countries, mixing regulated and non-regulated markets like a seasoned bartender.

But here’s the twist: while revenues show periodic spurts, profitability has been volatile. The stock’s P/E (~39.7×) looks aspirational for a company with OPM ~7% and middling returns. So why the interest? Because Carbapenems, Macrolides, Anti-Hypertensives, and a diagnostics merger promise optionality. Optionality is Wall Street’s polite word for “maybe magic, maybe mirage.”

Is Kopran a value trap or a slow-burn turnaround? Let’s dissect—scalpel in one hand, sarcasm in the other.

3. Business Model – WTF Do They Even Do?